AzTrials
AzTrials

CancerPhase 1NCT01938443

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

A Phase 1 study testing GSK2256098 and Trametinib in people with Cancer and Neoplasms, run by GlaxoSmithKline at 4 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the safety of combination treatment of GSK2256098 and trametinib in mesothelioma subjects and subjects with other selected tumor types. Also, the study will identify a maximum tolerated combination dose of GSK2256098 and trametinib. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer, Neoplasms
What is being tested?
GSK2256098 and Trametinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
34 participants
Where
4 sitesin 2 countries
Study dates
18 Nov 2013to 23 Jun 2016
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Part 1 Subject Inclusion Criteria:
  • Subjects with measurable tumors that may benefit from treatment with GSK2256098 and trametinib. This includes mesothelioma along with tumors with a high likelihood of MAPK pathway activation as reported in the medical literature.
  • Part 2 Subject Inclusion Criteria:
  • Histologically- or cytologically- confirmed diagnosis of recurrent or progressive, unresectable MPM with measurable lesion.
  • Part 1 and Part 2 Subject Inclusion Criteria:
  • Written informed consent provided.
Show all 11Show fewer
  • Males and females >=18 years of age (at the time consent is obtained).
  • Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
  • Able to swallow and retain orally administered study treatment.
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use effective contraception as per study protocol specification. Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as as per study protocol specification.
  • Adequate organ system functions as defined in the protocol

Who cannot join

  • Mesotheliomas originating outside of the pleural cavity (e.g., peritoneal mesothelioma) are excluded in the Pharmacodynamic Cohort in Part 1 and Part 2, but are permitted in Dose Escalation Cohorts in Part 1.
  • Subjects with leptomeningeal or brain metastases or spinal cord compression.
  • Use of an investigational anti-cancer drug within 28 days or five half-lives with a minimum duration of 10 days from prior therapy preceding the first dose of GSK2256098/trametinib OR Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C) OR any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. NOTE: Limited palliative radiation (i.e., duration typically < 15 days) with last dose >=6 weeks preceding the first dose of combination treatment is acceptable provided subject meets all of the other eligibility criteria and radiotherapy port does not encompass all measurable tumor. In addition, prophylactic radiation therapy to the site of tumor biopsies (as per the standard of care) during the current study to prevent seeding of the needle tract/biopsy is acceptable and does not require dose modification.
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2256098 or trametinib.
  • Previous treatment with GSK2256098 or trametinib, as well as other MEK or FAK inhibitors.
  • Current use of a prohibited medication or requires any of these medications during treatment.
Show all 16Show fewer
  • Current use of warfarin for therapeutic anticoagulation. NOTE: Low molecular weight heparin is permitted. PT/PTT must meet the inclusion criteria.
  • Presence of an active gastrointestinal disease, or other condition known to interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
  • History or evidence of cardiovascular risk including any of the following: Left ventricle ejection fraction (LVEF) < lower limit of normal (LLN) per local institutional practice; A QT interval corrected for heart rate using the Fredericia's formula (QTcF) >=480 msec;History or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible; History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; History or evidence of current >= Class II congestive heart failure as defined by New York Heart Association; Treatment refractory hypertension defined as a blood pressure of systolic> 140 millimeter of mercury (mmHg) and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy; Patients with intra-cardiac defibrillators or permanent pacemakers; Known cardiac metastases;
  • Active interstitial lung disease or pneumonitis.
  • History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes); Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as: Evidence of new optic disc cupping, Evidence of new visual field defects and Intraocular pressure > 21 mmHg
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
  • History of another malignancy (excludes non-melanoma skin cancer). Exception: Subjects who have been continuously disease-free for 3 years or who have had complete resection of a non-invasive primary cancer within 3 years of enrollment. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above.
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  • Concurrent condition that in the Investigator's opinion would jeopardize compliance with the protocol.
  • Nursing female.

Trial locations and contacts

4 sites in 2 countries.

4 sites in 2 countries

United Kingdom3 sites

  • GSK Investigational Site

    London, W12 0HS

  • GSK Investigational Site

    London, W1G 6AD

  • GSK Investigational Site

    Newcastle upon Tyne, NE7 7DN

Other trials in United Kingdom

France1 site

  • GSK Investigational Site

    Villejuif, 94805

Other trials in France

About this study

Official title: A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

The purpose of this study is to assess the safety of combination treatment of GSK2256098 and trametinib in mesothelioma subjects and subjects with other selected tumor types. Also, the study will identify a maximum tolerated combination dose of GSK2256098 and trametinib. This study is a Phase I, open-label, dose-escalation study to determine maximal tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and regimens for oral MEK inhibitor trametinib (once daily [OD]dosing) and the oral FAK inhibitor GSK2256098 (twice daily [BID] dosing). The synergy of the combination was observed over a wide range of concentrations and results in several-fold reduction in compound concentration to achieve equivalent biological responses compared to either single agent. The dose and schedule of dosing may be modified based on emerging safety, pharmacokinetic (PK), and pharmacodynamic (PD) data. The study will be conducted in two parts; Part 1 Dose Escalation to determine the MTD and RP2D and Part 2 Expansion Cohort to further evaluate the safety and tolerability of trametinib and GSK2256098 at the RP2D and determine clinical activity. Additionally, in Part 1 Dose Escalation, additional subjects with malignant pleural mesothelioma (MPM) will be recruited at doses that are considered tolerable in order to assess PD in MPM subjects at each dose (the Pharmacodynamic Cohort). The Expansion Cohort will be limited to subjects with MPM who have progressed or are intolerant to first-line therapy.

Conditions
Cancer, Neoplasms
Being tested
GSK2256098, Trametinib
Keywords
pharmacodynamics, MEK inhibitor, Focal adhesion kinase inhibitor, cancer, pharmacokinetic, mesothelioma, Phase 1
Medical subject headings
Neoplasms, Mesothelioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GSK2256098Drug

    GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.

  • TrametinibDrug

    Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.

Study groups in NCT01938443
Study groupRoleWhat they receive
Part 1ExperimentalPart 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
Receives: Drug: GSK2256098; Drug: Trametinib
Part 2ExperimentalBased on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
Receives: Drug: GSK2256098; Drug: Trametinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)

    AEs and SAEs will be assessed to determine the MTD and RP2D combination of GSK2256098 and trametinib.

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  2. Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)

    Twelve lead ECGs will be obtained to determine the MTD and RP2D combination of GSK2256098 and trametinib.

    Measured: Screening, Day 1, Day 15, Day 22, and every 8 weeks from first dose till post study visit (approximately 21 days from last dose)

  3. Part 1: Safety assessment as assessed by vital signs

    Vital sign measurements will include systolic and diastolic blood pressure, pulse rate, and temperature

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  4. Part 1: Safety assessment as assessed by change from baseline in laboratory values

    Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  5. Part 1: Safety assessment as assessed by echocardiogram

    Echocardiograms will be performed to assess cardiac ejection fraction.

    Measured: Screening, Day 28 and Day 1 of Weeks 13, 21, 33, then every 12 weeks.

  6. Part 1: Safety assessment as assessed by eye examination

    A standard ophthalmic exam will be performed by an ophthalmologist.

    Measured: Screening and as clinically warranted

  7. Part 1: Safety assessment as assessed by urine protein to creatinine (UPC) ratio

    Urine samples will be collected for the analyses of UPC ratio.

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  8. Part 2: Long term safety assessment as assessed by AEs and SAEs

    AEs and SAEs will be recorded to assess longer term safety of the GSK2256098/trametinib combination at the RP2D in a larger cohort of subjects with MPM.

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  9. Part 2: Long term safety assessment as assessed by 12-lead ECG

    Twelve lead ECGs will be obtained to assess longer term safety of the GSK2256098/trametinib combination at the RP2D in a larger cohort of subjects with MPM

    Measured: Screening, Day 1, Day 15, Day 22, and every 8 weeks from first dose till post study visit (approximately 21 days from last dose)

  10. Part 2: Long term safety assessment as assessed by vital signs

    Vital sign measurements will include systolic and diastolic blood pressure, pulse rate, and temperature

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  11. Part 2: Long term safety assessed as change from baseline in laboratory values

    Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

  12. Part 2: Long term safety assessment as assessed by echocardiogram

    Echocardiograms will be performed to assess cardiac ejection fraction.

    Measured: Screening, Day 28 and Day 1 of Weeks 13, 21, 33, then every 12 weeks.

  13. Part 2: Long term safety assessment as assessed by eye examination

    A standard ophthalmic exam will be performed by an ophthalmologist.

    Measured: Screening and as clinically warranted

  14. Part 2: Long term safety assessment as assessed by UPC ratio

    Urine samples will be collected for the analyses of UPC ratio.

    Measured: From Day 1 till post study visit (approximately 21 days from last dose)

Secondary outcomes (10)

  1. Part 1: GSK2256098 and trametinib PK assessment following repeat-dose (Day 15) administration of GSK2256098 and trametinib

    Blood sample will be collected for measurements of GSK2256098 and trametinib PK parameters including AUC(0-tau), Ctau, Cmax, and tmax.

    Measured: Day 15 (pre-dose, 1, 1.5, 2, 4, 6, 8 hours)

  2. Part 1: Tumor response and analysis of change from baseline levels of PD markers including pFAK/FAK, and pERK/ERK measured in tumor biopsies

    PD markers pFAK/FAK, and pERK/ERK levels will be analyzed in fresh tumor tissue to assess the level of target inhibition by GSK2256098 and trametinib, respectively. Tumor tissue will be collected at screening (before the first dose on Day 1) and between 1 and 6 hours after GSK2256098 dosing on a day between Day 15 and Day 22, inclusive.

    Measured: Screening (before the first dose on Day 1), Day 15 and 22

  3. Part 2: Tumor response as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) for mesothelioma

    CT and MRI scans.

    Measured: Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)

  4. Part 2: Change from baseline in observer assessed components of the Lung cancer symptom scale (LCSS)-mesothelioma

    The LCSS- mesothelioma is a disease- and site-specific quality of life instrument to measure physical and functional dimensions in patients with lung cancer. The LCSS- mesothelioma will be completed by the investigator at each scheduled disease assessment and at progression.

    Measured: Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)

  5. Part 2: Change from baseline in forced vital capacity

    Forced vital capacity will be measured at each scheduled disease assessment using standard methods.

    Measured: Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)

  6. Part 2: Progression-free survival (PFS)

    PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause by investigator assessment.

    Measured: Day 1 up to disease progression or death due to any cause

  7. Part 2: Change from baseline in patient reported components of the LCSS-mesothelioma

    The LCSS- mesothelioma is a disease- and site-specific quality of life instrument to measure physical and functional dimensions in patients with lung cancer. The LCSS- mesothelioma will be completed by the by the subjects with mesothelioma at each scheduled disease assessment and at progression.

    Measured: Baseline and every 8 weeks from first dose till disease progression and post study (21 days from last dose)

  8. Part 2: GSK2256098 and trametinib PK parameters following repeat-dose (Day 22) administration of GSK2256098 and trametinib

    Blood samples will be collected to analyze the PK parameters including AUC (0 tau), Ctau, Cmax, and tmax . If data permitting, population PK parameters, such as oral clearance (CL/F) and oral volume of distribution (Vz/F) of GSK2256098 and trametinib may be determined.

    Measured: Day 8 (pre-dose), 15 (pre-dose),22 (pre-dose, 1, 1.5,2,4,6 and 8 hrs), 29 and 57

  9. Part 2: Exploratory analysis between PK parameters, change from baseline levels of PD markers including pFAK/FAK, pERK/ERK measured in tumor biopsies, and tumor response

    The relationship between GSK2256098 and trametinib PK, PD and clinical endpoints in subjects with MPM will be assessed.

    Measured: Day 8, 15, 22, 29, and 57

  10. Part 1 and 2: GSK2256098 dried blood spot (DBS) and whole blood PK parameter following repeat-dose (Day15 and 22) administration of GSK2256098 and trametinib

    Blood samples will be collected to analyses PK parameters includes area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments [AUC(0-tau)], maximum observed plasma concentration (Cmax), time to Cmax (tmax), and trough concentration (Ctau) of GSK2256098 DBS and whole blood following repeat-dose (Day15 and 22) administration of GSK2256098 and trametinib.

    Measured: Day 15 and 22

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2013 (estimated)
  2. Study start18 Nov 2013
  3. Primary completion23 Jun 2016
  4. Study completion23 Jun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
34 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01938443
Sponsor's protocol ID
114746
Other IDs
2013-000784-85
Status last verified
Jul 2019
First submitted
5 Sep 2013
Last updated
12 Jul 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
Yes: IPD for this study will be made available via the Clinical Study Data Request site.

Publications

  • Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer. 2019 May;120(10):975-981. doi: 10.1038/s41416-019-0452-3. Epub 2019 Apr 17.

    PubMed 30992546

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing GSK2256098 and Trametinib in people with Cancer and Neoplasms, run by GlaxoSmithKline at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United Kingdom, France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs) (time frame: From Day 1 till post study visit (approximately 21 days from last dose)). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01938443, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2019.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in